Clarissa Martinez, PhD, Parkinson’s Foundation Director of Research & Centers Programs, speaks about the Foundation’s initiatives to increase the number of movement disorder specialists, reach underserved PD populations and about the Parkinson’s Outcomes Project (In Spanish).
Christopher Jamele, Parkinson's Foundation Western New York executive director, talks about how raising Parkinson’s awareness has an enormous impact.
Moving Day is more than just a walk. It raises awareness and funds to improve the lives of people living with Parkinson’s disease and advance toward a cure. This inspiring event brings together people of all ages and abilities for family-friendly fun and activities. Moving Day highlights movement and exercise as symbols of hope and progress because of their essential role in treating Parkinson’s disease. Take part in a variety of movement activities such as yoga, Tai Chi, boxing, dance, and much more. Whether you are part of a team or join as an individual, you’ll get a chance to move with hundreds of supporters who share a common goal – to help beat Parkinson’s. Register today!
John Lee has been living with PD for 5 years. He talks about symptoms and how movement can help. He promotes Moving Day Little Rock, its exercise demonstrations, how it is a great opportunity to network with other people going through the same thing and a chance to get good information about PD.
Colleen Fischer, Parkinson’s Foundation National Coordinator of Signature Events, speaks to local CBS reporter about Parkinson’s and Moving Day Sacramento. She speaks about how participants come together at Moving Day to share the common goal to beat Parkinson's.
Please come join us to hear expert speaker, Pamela Palmentera LCSW, Coordinator of the Parkinson’s Disease and Movement Disorder Center at Northwestern Memorial Hospital, speak on Parkinson's Disease and Mindfulness. Event is from 2pm-3pm, and there is no fee to attend.
On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.